Phase 3 Study Results of Zenkuda™ in Diabetic Retinopathy
The GLOW2 Phase 3 study reveals the effectiveness of Zenkuda™ (tarcocimab tedromer) in treating diabetic retinopathy compared to a sham treatment.
Topline Results from GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrate Superiority of Zenkuda (tarcocimab tedromer) Over Sham
Phase 3 Study Results of Zenkuda™ in Diabetic Retinopathy Page 2